Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prontoderm is an antimicrobial medical product available as a nasal gel, solution, and foam, mainly indicated for the decolonization of multidrug-resistant organisms (MDROs), especially methicillin-resistant Staphylococcus aureus (MRSA), from skin and nasal mucosa. The active ingredient is polyaminopropyl biguanide (polyhexanide, PHMB), a cationic antiseptic that acts by disrupting microbial cell membranes, thereby eliminating bacteria physically and inhibiting their growth, spreading, and transmission. Prontoderm is used in hospitals, nursing homes, and homes for both pre-operative cleansing and general MRDO decolonization. It provides a sustained antimicrobial barrier effect and is designed not to irritate or dry the skin or mucous membranes. It is well tolerated, dermatologically tested, and suitable for long-term use[3][4][5][6][8][10]. Developed by B. Braun, it is used in clinical settings to prevent surgical site infections and reduce transmission risk of resistant bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prontoderm.